Objective To determine the accuracy of the BPW810 blood pressure monitor developed by IDT Technology Limited, according to the international protocol of the European Society of Hypertension.
Introduction
The use of automatic blood pressure (BP) monitors has increased dramatically over the past few years owing to public's better awareness of the risk of having high BP [1] . In the meantime, health-care providers are encouraging patients with hypertension to measure their BP at home and currently use home-measured values for the management of their disease [2] [3] [4] .
The self-measurement of BP at home shares some of the advantages of ambulatory BP monitoring [5] , that is, the lack of a white-coat effect and the ability to be better than office values during diagnosis. A disadvantage of the automatic BP monitor is that body movements or an irregular heart rate affects the accuracy. In addition, the monitor requires batteries. Some models are designed for use with the left arm only. This may make them hard for some patients to use. Finally, some automatic BP monitors are expensive [6] . Moreover, the accuracy and reliability of automatic BP monitors used by patients has been of some concern [7]. In addition, most records in patients' reports have not been validated and approved before they are introduced into the market. So these instruments need to pass clinical tests by testing them against auscultatory measurements from a mercury sphygmomanometer according to international guidelines. The Working Group on Blood Pressure Monitoring of the European Society of Hypertension recently designed a new protocol for the evaluation of a BP measuring device, in order to make the validation process easier and more accurate [8, 14] . This paper mainly reports on the accuracy and reliability of the Oregon Scientific BPW810 (IDT Technology Ltd, Hong Kong, China), clinically evaluated according to the protocol of the Working Group on Blood Pressure Monitoring of the European Society of Hypertension [9] .
Method

Basic information about BPW810
The device number is BPW810, cuff circumference 13.5-19.5 cm, measuring range 30-280 mmHg (pressure) and heart rate 40-200 beats (pulses/minute). The device can give voice instructions for measuring preparation and operating, and after each measurement, it reads out the BP value, and also interprets BP classification according to the World Health Organization and the International Society of Hypertension guidelines.
Validation procedure
The device evaluation was performed according to the international protocol. A standard mercury sphygmomanometer, Rieser DIPLOMAT Presameter-Desk model (Rudolf Riester GmbH & Co., Jungingen Germany), was used with a Riester Tristar stethoscope (Rudolf Riester GmbH & Co.). Before the study, all the components were carefully checked, and the mercury sphygmomanometer was calibrated by a digital pressure calibrator. The BP measurement technique follows a booklet -Recommendations on blood pressure measurementpublished by the British Medical Journal, London, UK. The validation team consisted of three persons experienced in BP measurement having undergone a training procedure mentioned in Ref. [8] -appendix B. Observer training: They were tested against each other and against a supervisor. Ten measurements were taken by each observer on each of the five participants, giving a total of 50 measurements for each observer. The observers satisfied the training criteria and the results are shown in Table 1 .
Two of the three observers measured BP using the standard mercury sphygmomanometer, and the third observer was the supervisor who measured BP with the test device BPW810. Measurements made simultaneously by the two observers were checked by the supervisor. If the systolic blood pressure (SBP) and diastolic blood pressure (DBP) measurements are no more than 4 mmHg apart, the mean value of the two observers' measurements for SBP and DBP was used. Otherwise, the measurement was taken again. The validation team read the manual thoroughly and made sure all operations of the BPW810 followed the instruction in the manual. The measurements were taken using a correctly sized cuff. The standard cuff was used if the wrist circumference was from 13.5 to 19.5 cm. Analysis according to the international protocol consisted of two phases. In the first phase, 15 subjects were recruited; device passing phase, one can then proceed to the phase two, for which a further 18 subjects were recruited.
Participant selection
Test participants were selected according to the international protocol so that the participant population reflected a wide range of age, sex, arm circumference and BP values. For the first phase, there were at least five men and five women among the 15 participants; for the second phase there were at least 10 men and 10 women among the 33 participants. All participants should be at least 30 years of age. The arm circumference of participants is randomly distributed. During phase 1, five of 15 participants should have SBP in each of the ranges (Table 2) . Similarly, five of the 15 participants should have DBP in each of the ranges ( Table 2) . During phase 2, 11 of the 33 participants (including the first 15 participants) should have SBP and DBP in each of the ranges ( Table 2 ). Three ranges for SBP and three for DBP were noted, with 11 participants in each range, to provide 99 pairs of measurements.
Procedure
The participant is introduced to the observers and the procedure is explained. Arm and wrist circumference, sex, date of birth and current date and time are noted. The participant is then asked to relax for 10-15 min. BP measurements with BPW810 are taken on the left wrist at the heart level and on the left arm with a sphygmomanometer. BP is measured simultaneously (Y tube) with two calibrated mercury sphygmomanometers by the two observers alternately with the automated device. The observers were blinded to each other's reading. Nine sequential same-arm measurements using the testing instrument and a standard mercury sphygmomanometer are recorded as follows: BPA Entry blood pressure, observers 1 and 2 each with the mercury standard. The mean values are used to categorize the subject into a low, medium or high range separately for SBP and DBP ( Table 2) . BPB
Device detection blood pressure, the supervisor. This blood pressure is measured to allow the test instrument to determine the blood pressure characteristics of the participant; more than one attempt may be needed with some advices; this measurement is not included in the analysis. If the device fails to record a measurement after three attempts, the participant is excused. BP1
Observers 1 and 2 with the mercury standard.
BP2
Supervisor with the test instrument. BP3
BP4
Supervisor with the test instrument. BP5
BP6
Supervisor with the test instrument. BP7
Accuracy criteria
The international protocol introduced the concept of classifying the difference between test and control measurements according to whether these lay within 5, 10 or 15 mmHg. Differences are always calculated by subtracting the observer measurement from the device measurement. A difference is categorized into one of three bands according to its rounded absolute value for SBP and DBP separately.
Participant measurements
For assessment of accuracy, only measurements BP1-BP7 are used. The mean of each pair of observer measurements is calculated; this is denoted as observer measurements BP1, BP3, BP5 or BP7. Each device measurement is flanked by two of these observer measurements, and one of these is selected as the comparative measurement.
From these, further measurements are derived as follows:
1. The differences BP2 -BP1, BP2 -BP3, BP4 -BP3, BP4 -BP5, BP6 -BP5 and BP6 -BP7 are calculated. 2. The absolute values of the differences are calculated. 3. These are paired according to the device reading. 4. If the values in a pair are unequal, the observer measurement corresponding to the smaller difference is used. 5. If the values in a pair are equal, the first of the two observer measurements is used.
When this has been completed, there are three device readings for SBP and three for DBP for each participant. Each of these six readings has a single corresponding observer measurement, a difference between the two and a band for that difference as described.
Assessment
Once there are 11 participants in each of the six BP ranges ( Table 2) , recruitment should be stopped and assessment performed. Data from only the first five participants in each range are used. This will yield 45 sets of measurements for both SBP and DBP for the first phase (15 participants) and 99 sets for the second phase (33 participants). The number of differences in each zone is calculated and compared with the number required by the international protocol and a continue/ fail grade is determined for the first phase and a pass/ fail grade for second phase (phase 2.1). If the device fails at the first phase, the validation is complete. In addition, for the second phase, the number of differences falling within 5, 10, 15 mmHg determines a pass/fail grade for 33 subjects and a pass/fail recommendation is determined (Table 4 ). To pass the validation and be recommended for clinical use a device must pass both phases 2.1 and 2.2. If it does not, it fails and is not recommended for clinical use.
Result
The characteristics of the 33 participants are shown in Table 3 . The mean age of the participants was 51 years (19 men and 14 women). The wrist circumferences range is 16.5 ± 1.1 cm (range = 14.5-18.5 cm). The standard cuff, which is suitable for wrist circumferences range 13.5-19.5 cm, was used in this validation. The auscultatory BP measurements lie in the range 92-190 mmHg for SBP and 66-126 mmHg for DBP, which covers a wide range of BP. In total, the results of the number of measurements differing from the mercury standard by within 5, 10 and 15 mmHg are shown in Table 4 . These results are in concordance with the requested criteria of the international protocol for primary and secondary phases.
In phase 1, 45 sets of measurements were available for analysis. As shown in Table 4 , for SBP, 32, 39 and 44 device measurements fell in zones within 5, 10 and 15 mmHg, respectively; for DBP, 38, 45 and 45 device measurements fell in zones within 5, 10 and 15 mmHg, respectively. Therefore, phase 1 was passed and participants could take the phase 2 test.
In phase 2.1, 99 sets of measurements were available for analysis. In the sample of 33 participants, the measurements falling in zones within 5, 10 and 15 mmHg were 77, 90 and 96 for SBP and 81, 98 and 99 for DBP, respectively. Thus, phase 2 was also successfully completed (phase 2.1).
Finally, we conducted the analysis required for the last phase (phase 2.2). In the case of the device tested, the measurements completed on 33 participants showed that 26 participants fell in the zone of two of the three comparisons lying within 5 mmHg and none of the participants fell in the zone of all three of the comparisons over 5 mmHg apart for SBP; 29 participants fell in the zone of two of the three comparisons lying within 5 mmHg and none of the participants fell in the zone of all three of the comparisons over 5 mmHg apart for DBP. Thus, the last phase was also successfully completed. So the BPW 810 device fulfills the validation criteria of the international protocol.
The difference between the device readings and observer readings and the mean BP from the device and the two observers for all 99 points for SBP and DBP are displayed in Fig. 1 .
Discussion
BPW 810 is validated for SBP and for DBP according to the international protocol. The international protocol recommendations were published in 2002 by the Working Group on Blood Pressure Monitoring of the European Society of Hypertension [8] aimed at simplifying the two main available guidelines, the British Hypertension Society [8] and Association for the Advancement of Medical Instrumentation [10] protocols, without sacrificing their integrity. These two validation protocols have many similarities but experience has demonstrated that the conditions they recommend are sometimes extremely difficult to fulfill especially because of the large number of participants who have to be recruited and the ranges of BP required. It has been demonstrated by the European Society of Hypertension that validation studies can be performed in such a way as to satisfy the criteria of these much more complicated earlier protocols. The main advantage of the international protocol is that it requires a fewer number of participants, 33 instead of 85 as in the two previous protocols [11] . Plot for systolic blood pressure (SBP) and diastolic blood pressure (DBP) (means of observers and device readings) versus the difference between the BPW810 and the mercury sphygmomanometer (the red dots indicate two data; the green dots indicate three data). Table 4 , BPW810 passed the international protocol that considers not only 'individual measurements' (77 systolic and 81 diastolic readings falling within 5 mmHg, this exceeding the 65 for SBP and 60 for DBP required for approval), but also 'individual participants' (the number of participants with at least two of their BP comparisons falling within 5 mmHg -26 for SBP and 29 for DBP, exceeding the 22 required) by determining the number of differences falling within 5, 10 and 15 mmHg, and determining the accuracy. As BPW 810 passed phase 2.1 and 2.2, it passes the validation and can be recommended for clinical use in adult populations.
As shown in detail in
From another aspect, self-monitoring of BP at home can accomplish several of the advantages of ambulatory BP monitoring over clinic measurements: by allowing multiple reading averaged over time and by taking measurements in people's usual environment, a more reproducible BP value is produced that is devoid of the white-coat syndrome [12] . Most national and international hypertension guidelines include some recommendations for home BP measurement [13] . For diagnostic purposes, some experts propose duplicate measurements every morning and evening during a 7-day period, sometimes with exclusion of the readings of the first day [13] . So, home BP measurement may improve control of BP by improving compliance, as patients become more involved in their care. It might also reduce healthcare costs by reducing the number of clinic visits. Home BP monitoring can provide supplementary information to practicing doctors enabling a more precise diagnosis and more accurate titration in long-term follow-up of hypertension. The analysis shows that the BPW810 provides accurate and reliable BP measurements and is capable of generating precise BP readings across a wide spectrum of individuals: BPW810 provides two different users with 60 memories each that can help the user to record the BP history readings with date and time stamps; we thus recommend BPW810 as a home BP monitoring device.
